Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.36 Insider Own0.50% Shs Outstand215.42M Perf Week-3.19%
Market Cap16.98B Forward P/E- EPS next Y-1.20 Insider Trans-15.20% Shs Float219.68M Perf Month-0.87%
Income-506.40M PEG- EPS next Q-0.17 Inst Own92.70% Short Float2.04% Perf Quarter51.83%
Sales1.42B P/S11.98 EPS this Y-464.30% Inst Trans1.65% Short Ratio1.81 Perf Half Y88.56%
Book/sh3.46 P/B22.77 EPS next Y44.20% ROA-19.30% Target Price92.48 Perf Year40.87%
Cash/sh5.75 P/C13.70 EPS next 5Y6.50% ROE-53.20% 52W Range38.44 - 87.47 Perf YTD88.07%
Dividend- P/FCF144.22 EPS past 5Y30.00% ROI-2.60% 52W High-9.91% Beta0.39
Dividend %- Quick Ratio3.80 Sales past 5Y50.30% Gross Margin80.00% 52W Low104.99% ATR3.24
Employees2200 Current Ratio3.80 Sales Q/Q-25.10% Oper. Margin-8.00% RSI (14)45.52 Volatility4.59% 4.14%
OptionableYes Debt/Eq0.99 EPS Q/Q-432.60% Profit Margin-35.80% Rel Volume0.80 Prev Close78.75
ShortableYes LT Debt/Eq0.98 EarningsApr 30 AMC Payout- Avg Volume2.47M Price78.80
Recom1.90 SMA20-1.13% SMA505.29% SMA20042.69% Volume1,967,848 Change0.06%
01-May-13Reiterated UBS Buy $60 → $86
19-Apr-13Upgrade Canaccord Genuity Hold → Buy $55 → $96
19-Apr-13Reiterated RBC Capital Mkts Outperform $70 → $95
19-Apr-13Reiterated Needham Buy $65 → $95
19-Apr-13Reiterated Maxim Group Buy $60 → $88
19-Apr-13Reiterated Deutsche Bank Buy $75 → $100
19-Apr-13Reiterated Chardan Capital Markets Buy $80 → $105
19-Apr-13Reiterated Barclays Overweight $68 → $95
10-Apr-13Initiated Chardan Capital Markets Buy $80
07-Feb-13Initiated Robert W. Baird Outperform $53
11-Jan-13Reiterated Barclays Overweight $69 → $68
28-Nov-12Downgrade Argus Buy → Hold
04-Oct-12Initiated Argus Buy $68
27-Jun-12Initiated Maxim Group Buy $86
08-May-12Upgrade Needham Hold → Buy $65
08-May-12Reiterated Needham Buy $65
08-May-12Reiterated Barclays Overweight $44 → $77
11-Apr-12Reiterated Barclays Overweight $45 → $44
28-Mar-12Reiterated UBS Neutral $35 → $44
01-Feb-12Reiterated Barclays Capital Overweight $38 → $44
18-Jun-13 04:45PM  Vertex Pharmaceuticals Moves Up In Market Cap Rank, Passing Intuit at Forbes
08:30AM  Vertex Completes Redemption of Convertible Senior Subordinated Notes Business Wire
17-Jun-13 11:45AM  3 High Risk Hot Stocks To Watch at TheStreet
08:17AM  Gilead's Potential Megablockbuster Raises the Bar at Motley Fool
14-Jun-13 12:22PM  Commit To Purchase Vertex Pharmaceuticals At $55, Earn 13.3% at Forbes
07:25AM  Vertex CF data positive, says RBC Capital theflyonthewall.com
13-Jun-13 02:57PM  These Mutated Cystic Fibrosis Cells Are Worth Billions to Vertex Pharma at TheStreet
09:39AM  Inside HCV: An Interview with Janssen at Motley Fool
11-Jun-13 07:36PM  Game-Changing Hep C Pill Closer to Approval at Motley Fool
05:01PM  Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard at TheStreet
04:50PM  Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 10:00 AM at Seeking Alpha
02:37PM  SMC posts decision on Kalydeco resubmission to website theflyonthewall.com
09:00AM  Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales at TheStreet
10-Jun-13 01:03PM  5 Drugs Stocks Dragging The Industry Down at TheStreet
06-Jun-13 03:11PM  [video] Biotech's Next Big Thing: Vertex at TheStreet
07:00AM  Remember Vertex? Important Cystic Fibrosis Data On Tap Next Week at TheStreet
05-Jun-13 05:30PM  Vertex Announces Webcast of its Presentation at the Goldman Sachs 34th Annual Global Healthcare Conference Business Wire
10:22AM  InPlay: Vertex Pharm announces presentation of data at European Cystic Fibrosis Society Conference Briefing.com
10:21AM  Vertex Announces Presentation of Data at European Cystic Fibrosis Society Conference Business Wire
06:32AM  3 Pharmaceuticals With Strong Potential at Seeking Alpha
03-Jun-13 04:00PM  New drugs trail many old ones in effectiveness against disease at Reuters
31-May-13 01:46PM  Stocks to Buy: Biotechs With Growth Potential at Motley Fool
12:51PM  3 Significant Insider Sells in Healthcare Worth Noting at Motley Fool
12:25PM  Will Hepatitis C Become A New Battleground Between Pharma And Poor Nations? at Forbes
11:27AM  The Race For Oral HCV? at Seeking Alpha
12:21AM  4 Companies Riding the Orphan Drug Rocket at Motley Fool
30-May-13 05:00PM  Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Winner at TheStreet +6.06%
08:01AM  5 Best Biotechs of 2013 at Motley Fool
08:00AM  Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection Marketwired
08:00AM  Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection Marketwire
29-May-13 02:05PM  Johnson & Johnson Stock Takes a Breather at Motley Fool
28-May-13 10:15AM  3 Signs Irrational Exuberance Is Back at Motley Fool
23-May-13 02:44PM  1 Tech, 1 Biotech And 1 Business Services Company With Recent Intensive Insider Selling at Seeking Alpha
20-May-13 01:04PM  5 Stocks Underperforming Today In The Drugs Industry at TheStreet
07:38AM  Pharma's R&D Deals With Foundations May Negatively Impact Image at Forbes
17-May-13 11:07AM  Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to Investing Wall Street Transcript
08:31AM  InPlay: Vertex Pharm calls for redemption of $400 mln of its 3.35% Convertible Senior Subordinated Notes due 2015 Briefing.com
08:30AM  Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015 Business Wire
01:42AM  VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct Financial EDGAR Online
16-May-13 05:01PM  Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard at TheStreet
03:38PM  A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street Transcript Wall Street Transcript
11:06AM  2 Scariest Dividend Stocks in Health Care at Motley Fool
15-May-13 01:03PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
08:21AM  Racing Toward the Next Hepatitis C Drug Approval at Motley Fool
14-May-13 01:04PM  VERTEX PHARMACEUTICALS INC / MA Financials EDGAR Online Financials
13-May-13 02:31AM  This Stock Deserved Its Sudden Upswing at Seeking Alpha
11-May-13 09:32AM  3 Investment Strategy Lessons From Vertex's Success at Motley Fool
09-May-13 06:07PM  Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences Business Wire
03:36AM  Did This Stock Deserve This Sudden Upward Swing? at Motley Fool
03:25AM  Vertex Debt Conversion Is Not Bad For Shareholders at Seeking Alpha
08-May-13 01:22PM  Double-Digit Returns from the Biotechnology Strategy at Motley Fool
12:10PM  Orphan Drug Companies Might Not Find A Parent at Forbes
09:36AM  VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements EDGAR Online
09:34AM  VERTEX PHARMACEUTICALS INC / MA Files SEC form 10-Q, Quarterly Report EDGAR Online
07-May-13 02:40PM  Half of Hepatitis C Patients Dont Get Full Testing, CDC Says at Bloomberg
01:29PM  Many in U.S. don't get proper testing for hepatitis C- CDC at Reuters
06-May-13 01:03PM  3 Stocks Improving Performance Of The Health Care Sector at TheStreet
06:28AM  [$$] Gilead Sciences Enters a New Phase at Barrons.com
03-May-13 10:18PM  Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential at Seeking Alpha
05:01PM  Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard at TheStreet
04:56PM  Gilead Sciences climbs to all-time highs AP
11:43AM  Drug Manufacturers and the FDA Collaborate More Closely for Faster Drug Approval: An Exclusive Interview with an Expert Equity Analyst Reveals Some Top Stock Picks in This Vital Industry Wall Street Transcript
07:54AM  Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares at Seeking Alpha
02-May-13 06:36PM  Gilead's HCV Drug Pipeline Outshines Weak Q1 Results at Investor's Business Daily
04:22PM  Gilead Misses Analysts Estimates on Sales of HIV Drugs at Bloomberg
02:06AM  Vertex Q1 Results Worse Than 2012, but Better Than Expected at Motley Fool
01-May-13 09:14PM  Take 2 Dividend Stocks and Call Me in the Morning at Motley Fool
11:17AM  Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform at Seeking Alpha
11:08AM  Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs: A Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc. Wall Street Transcript
09:55AM  3 Healthcare Picks From Janus Fund at Motley Fool
08:22AM  Vertex Loss Lower, Kalydeco Outlook Up Zacks
30-Apr-13 09:50PM  Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
05:58PM  Vertex Pharmaceuticals Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet
04:42PM  UPDATE 1-Vertex posts loss, raises cystic fibrosis drug sales view at Reuters
04:30PM  InPlay: Vertex Pharm beats by $0.09, beats on revs; guides FY13 revs in-line Briefing.com
04:23PM  Vertex posts quarterly loss as hepatitis C drug sales fall at Reuters
04:03PM  Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C Business Wire
09:25AM  VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
07:07AM  Q1 2013 Vertex Pharmaceuticals Incorporated Earnings Release - After Market Close CCBN
29-Apr-13 01:23PM  Top Undervalued Pharma Stock: Analyst at CNBC
11:00AM  FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market: A Wall Street Transcript Interview with Brian Skorney, Senior Analyst at Robert W. Baird & Co. Wall Street Transcript
10:44AM  April's Top 10 Nasdaq 100 Stocks at Forbes
10:07AM  Vertex Pharmaceuticals Incorporated Earnings Preview: Can This Streak Finally End? at Wall St. Cheat Sheet
09:26AM  This Biotech Just Popped, and Might Pop Further at Motley Fool
05:51AM  NewLink Genetics: Looking To Join The Industry's Largest Movers at Seeking Alpha
28-Apr-13 12:14PM  Gilead-Bristol Hepatitis C Drug Combo Cures All in Study at Bloomberg
26-Apr-13 05:01PM  Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard at TheStreet
11:49AM  Mark A. Emalfarb, Founder, Chairman, President and CEO of Dyadic International (DYAI), Interviews with The Wall Street Transcript Wall Street Transcript
10:33AM  Forbes Earnings Preview: Vertex Pharmaceuticals Incorporated at Forbes
25-Apr-13 09:25AM  Sarepta: Staying Long and Strong at TheStreet
24-Apr-13 11:46AM  [video] Wednesday's Earnings Scorecard at CNBC
10:34AM  Cramer: Buy Vertex Pharma, But Sell Two Harbors Investments and These 2 Stocks at Wall St. Cheat Sheet
08:36AM  InPlay: Vertex Pharm announces new data that showed high viral cure rates with a total of 12 and 24 weeks of telaprevir combination treatment among people with genotype 1 hepatitis C who have the IL28B CC genotype Briefing.com
08:30AM  Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype Business Wire
07:11AM  Vertex CFO Rings Register On $35 Million Insider Sale at TheStreet
07:11AM  Vertex CFO Rings Register on $35 Million Insider Sale at TheStreet
06:45AM  Cramer's Lightning Round - EMC Is Controversial (4/23/13) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Apache Is a Dog at TheStreet
01:50AM  Vertex Spikes On Phase II Data, Then The CFO Sell His Shares at Seeking Alpha
23-Apr-13 05:40PM  Merck - BMY in HCV Deal Zacks
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOGER JOSHUA SDirectorJun 12Option Exercise9.071,40012,698340,295Jun 13 04:16 PM
BOGER JOSHUA SDirectorJun 12Sale81.191,400113,671338,895Jun 13 04:16 PM
BOGER JOSHUA SDirectorJun 05Option Exercise9.071,40012,698340,295Jun 06 04:34 PM
BOGER JOSHUA SDirectorJun 05Sale77.151,400108,015338,895Jun 06 04:34 PM
BOGER JOSHUA SDirectorMay 30Option Exercise9.071,40012,698340,295Jun 03 05:11 PM
BOGER JOSHUA SDirectorMay 30Sale82.471,400115,464338,895Jun 03 05:11 PM
BOGER JOSHUA SDirectorMay 22Option Exercise9.071,40012,698354,295May 23 04:13 PM
SACHS BRUCE IDirectorMay 22Sale79.778,300662,116104,610May 23 04:14 PM
BOGER JOSHUA SDirectorMay 22Sale79.721,400111,609352,895May 23 04:13 PM
BOGER JOSHUA SDirectorMay 15Option Exercise9.071,40012,698354,295May 17 04:12 PM
Stamoulis ChristianaSVP, Corp Strategy & Bus DevlpMay 15Sale79.6560247,94940,712May 17 04:15 PM
Silva Paul MSVP & Corp ControllerMay 15Sale79.6660948,51011,750May 17 04:14 PM
SMITH IAN FEVP & CFOMay 15Sale79.6760948,52124,168May 17 04:13 PM
BOGER JOSHUA SDirectorMay 15Sale79.361,400111,110352,895May 17 04:12 PM
SACHS BRUCE IDirectorMay 14Sale81.1560,0004,869,000112,910May 16 04:57 PM
Silva Paul MSVP & Corp ControllerMay 06Option Exercise39.0593736,59012,687May 08 04:22 PM
SACHS BRUCE IDirectorMay 06Sale77.228,300640,917172,910May 08 04:24 PM
Silva Paul MSVP & Corp ControllerMay 06Sale77.2193772,34311,750May 08 04:22 PM
Silva Paul MSVP & Corp ControllerMay 03Option Exercise38.8093736,35612,687May 06 04:29 PM
ULLIAN ELAINEDirectorMay 03Option Exercise29.8740,0001,194,60045,265May 07 04:30 PM
ULLIAN ELAINEDirectorMay 03Sale77.9940,0003,119,6005,265May 07 04:30 PM
Silva Paul MSVP & Corp ControllerMay 03Sale76.2093771,40311,750May 06 04:29 PM
Silva Paul MSVP & Corp ControllerMay 02Option Exercise37.861,12542,59312,875May 06 04:29 PM
Silva Paul MSVP & Corp ControllerMay 02Sale77.331,12586,99511,750May 06 04:29 PM
Stamoulis ChristianaSVP, Corp Strategy & Bus DevlpApr 30Option Exercise34.5713540,713May 01 04:27 PM
Stamoulis ChristianaSVP, Corp Strategy & Bus DevlpApr 30Sale77.8817840,712May 01 04:27 PM
Stamoulis ChristianaSVP, Corp Strategy & Bus DevlpApr 29Option Exercise34.4577,9992,687,144123,711May 01 04:27 PM
Stamoulis ChristianaSVP, Corp Strategy & Bus DevlpApr 29Sale79.5082,9996,598,75640,712May 01 04:27 PM
Silva Paul MSVP & Corp ControllerApr 25Option Exercise48.741,12554,83312,875Apr 29 04:40 PM
Silva Paul MSVP & Corp ControllerApr 25Sale80.591,12590,66911,750Apr 29 04:40 PM
SMITH IAN FEVP & CFOApr 19Option Exercise34.54739,64325,545,249769,853Apr 23 04:30 PM
Silva Paul MSVP & Corp ControllerApr 19Option Exercise40.6722,549917,05634,299Apr 23 04:31 PM
Silva Paul MSVP & Corp ControllerApr 19Sale81.5022,5491,837,74411,750Apr 23 04:31 PM
SMITH IAN FEVP & CFOApr 19Sale81.76745,68560,963,61224,168Apr 23 04:30 PM
LEIDEN JEFFREY MCEO & PresidentFeb 06Sale45.8333,3451,528,201192,371Feb 07 05:29 PM
BOGER JOSHUA SDirectorJan 02Option Exercise15.602,95146,036635,846Jan 03 04:18 PM
BOGER JOSHUA SDirectorJan 02Sale43.092,951127,159632,895Jan 03 04:18 PM
BOGER JOSHUA SDirectorDec 26Option Exercise15.604,00062,400636,895Dec 27 04:20 PM
BOGER JOSHUA SDirectorDec 26Sale41.864,000167,440632,895Dec 27 04:20 PM
BOGER JOSHUA SDirectorDec 19Option Exercise15.604,00062,400636,895Dec 20 04:46 PM
BOGER JOSHUA SDirectorDec 19Sale43.444,000173,776632,895Dec 20 04:46 PM
BOGER JOSHUA SDirectorDec 12Option Exercise15.604,00062,400636,895Dec 13 04:22 PM
BOGER JOSHUA SDirectorDec 12Sale42.074,000168,280632,895Dec 13 04:22 PM
BOGER JOSHUA SDirectorDec 05Option Exercise15.604,00062,400636,895Dec 06 04:20 PM
BOGER JOSHUA SDirectorDec 05Sale39.354,000157,400632,895Dec 06 04:20 PM
BOGER JOSHUA SDirectorNov 28Option Exercise15.604,00062,400636,895Nov 30 12:31 PM
BOGER JOSHUA SDirectorNov 28Sale39.344,000157,360632,895Nov 30 12:31 PM
BOGER JOSHUA SDirectorNov 21Option Exercise15.604,00062,400636,895Nov 26 03:27 PM
BOGER JOSHUA SDirectorNov 21Sale41.174,000164,660632,895Nov 26 03:27 PM
SMITH IAN FEVP & CFONov 16Sale41.266,042249,29318,126Nov 20 04:19 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicyNov 16Sale41.292,28794,43018,821Nov 20 04:18 PM
Emmens MatthewDirectorNov 16Sale41.7610,850453,096200,873Nov 20 04:18 PM
Kelly LisaSVP, Human ResourcesNov 16Sale41.282,03383,92215,216Nov 19 04:35 PM
Kelly LisaSVP, Human ResourcesNov 15Sale40.5935514,40917,249Nov 19 04:35 PM
BOGER JOSHUA SDirectorNov 14Option Exercise15.604,00062,400636,895Nov 16 02:45 PM
BOGER JOSHUA SDirectorNov 14Sale42.874,000171,480632,895Nov 16 02:45 PM
BOGER JOSHUA SDirectorNov 07Option Exercise15.604,00062,400636,895Nov 08 04:20 PM
MCGLYNN MARGARET GDirectorNov 07Buy45.501,00045,5001,000Nov 08 04:21 PM
BOGER JOSHUA SDirectorNov 07Sale45.464,000181,840632,895Nov 08 04:20 PM
BOGER JOSHUA SDirectorOct 31Option Exercise15.604,00062,400636,895Nov 02 04:27 PM
BOGER JOSHUA SDirectorOct 31Sale48.114,000192,438632,895Nov 02 04:27 PM
BOGER JOSHUA SDirectorOct 24Option Exercise15.604,00062,400636,895Oct 25 04:13 PM
BOGER JOSHUA SDirectorOct 24Sale49.384,000197,520632,895Oct 25 04:13 PM
BOGER JOSHUA SDirectorOct 17Option Exercise15.604,00062,400636,895Oct 18 04:18 PM
BOGER JOSHUA SDirectorOct 17Sale53.714,000214,857632,895Oct 18 04:18 PM
MUELLER PETEREVP, Global R&D, CSOOct 15Option Exercise16.326,500106,080138,816Oct 16 04:43 PM
MUELLER PETEREVP, Global R&D, CSOOct 15Sale52.936,500344,015132,316Oct 16 04:43 PM
SMITH IAN FEVP & CFOOct 11Option Exercise24.3514,043341,94338,211Oct 15 04:44 PM
SMITH IAN FEVP & CFOOct 11Sale60.0014,043842,58024,168Oct 15 04:44 PM
BOGER JOSHUA SDirectorOct 10Option Exercise15.604,00062,400636,895Oct 11 04:19 PM
BOGER JOSHUA SDirectorOct 10Sale57.154,000228,602632,895Oct 11 04:19 PM
SMITH IAN FEVP & CFOOct 08Option Exercise17.4143,949765,30368,955Oct 09 04:25 PM
SMITH IAN FEVP & CFOOct 08Sale60.0044,7872,687,22024,168Oct 09 04:25 PM
BOGER JOSHUA SDirectorOct 03Option Exercise15.604,00062,400636,895Oct 04 04:12 PM
BOGER JOSHUA SDirectorOct 03Sale57.744,000230,960632,895Oct 04 04:12 PM
BOGER JOSHUA SDirectorSep 26Option Exercise15.604,00062,400636,895Sep 27 04:14 PM
BOGER JOSHUA SDirectorSep 26Sale55.074,000220,290632,895Sep 27 04:14 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 21Option Exercise32.169,531306,51730,639Sep 25 04:07 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 21Sale59.009,531562,32921,108Sep 25 04:07 PM
BOGER JOSHUA SDirectorSep 19Option Exercise15.604,00062,400636,895Sep 20 04:19 PM
Kelly LisaSVP, Human ResourcesSep 19Option Exercise32.804,047132,75021,296Sep 21 04:25 PM
BOGER JOSHUA SDirectorSep 19Sale57.664,000230,640632,895Sep 20 04:19 PM
Kelly LisaSVP, Human ResourcesSep 19Sale57.614,047233,14817,249Sep 21 04:25 PM
MUELLER PETEREVP, Global R&D, CSOSep 17Option Exercise16.326,500106,080138,816Sep 19 05:05 PM
MUELLER PETEREVP, Global R&D, CSOSep 17Sale57.526,500373,880132,316Sep 19 05:05 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 14Option Exercise32.169,531306,51730,639Sep 17 04:26 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 14Sale58.009,531552,79821,108Sep 17 04:26 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 13Option Exercise30.2328,281854,95459,389Sep 17 04:26 PM
Sachdev AmitSVP, Corp Affairs & Pub PolicySep 13Sale56.1738,2812,150,30421,108Sep 17 04:26 PM
BOGER JOSHUA SDirectorSep 12Option Exercise15.604,00062,400636,895Sep 13 04:23 PM
BOGER JOSHUA SDirectorSep 12Sale55.704,000222,812632,895Sep 13 04:23 PM
BOGER JOSHUA SDirectorSep 05Option Exercise15.604,00062,400636,895Sep 06 04:08 PM
BOGER JOSHUA SDirectorSep 05Sale54.704,000218,800632,895Sep 06 04:08 PM
BOGER JOSHUA SDirectorAug 29Option Exercise15.604,00062,400636,895Aug 30 03:19 PM
BOGER JOSHUA SDirectorAug 29Sale53.454,000213,814632,895Aug 30 03:19 PM
BOGER JOSHUA SDirectorAug 22Option Exercise15.604,00062,400636,895Aug 23 03:58 PM
BOGER JOSHUA SDirectorAug 22Sale54.594,000218,360632,895Aug 23 03:58 PM
Kelly LisaSVP, Human ResourcesAug 16Option Exercise32.1695330,64818,202Aug 20 05:20 PM
Kelly LisaSVP, Human ResourcesAug 16Sale55.0095352,41517,249Aug 20 05:20 PM
MUELLER PETEREVP, Global R&D, CSOAug 15Option Exercise16.326,500106,080138,816Aug 17 02:19 PM
open in yahoo | open in reuters | open in google